Investor Alert: Securities Fraud Class Action Announcement by Bernstein Liebhard LLP

A securities fraud class action lawsuit has recently been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), according to a recent announcement made by law firm Bernstein Liebhard LLP.

The lawsuit alleges that Rocket Pharmaceuticals, Inc. made false and misleading statements regarding the company’s business operations and prospects. These statements allegedly resulted in inflated stock prices and caused financial harm to shareholders who purchased securities during the class period.

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare genetic disorders. The company’s stock price experienced significant fluctuations during the class period in question, which led to concerns regarding potential securities fraud.

Shareholders who purchased Rocket Pharmaceuticals, Inc. securities during the class period may be eligible to participate in the class action lawsuit. The lawsuit aims to hold the company accountable for any alleged false or misleading statements that may have impacted shareholders’ financial interests.

Investors are encouraged to contact Bernstein Liebhard LLP to learn more about their legal rights and options in regards to the securities fraud class action lawsuit against Rocket Pharmaceuticals, Inc. The law firm is committed to seeking justice for shareholders who may have been harmed by the alleged misconduct of the company.

Bernstein Liebhard LLP is a nationally recognized law firm specializing in securities litigation and class action lawsuits. The firm has a strong track record of success in representing investors and holding corporations accountable for fraudulent practices.

If you are a shareholder who purchased Rocket Pharmaceuticals, Inc. securities during the class period and are interested in learning more about the class action lawsuit, contact Bernstein Liebhard LLP today for a free consultation. Shareholders have rights and options when it comes to seeking justice for any financial harm they may have suffered as a result of alleged securities fraud.